The German Breast Group (GBG) and Pfizer Inc. (PFE) announced Friday that the collaborative Phase 3 PENELOPE-B trial of IBRANCE (palbociclib) in Early Breast Cancer did not meet the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early breast cancer (eBC) who have residual invasive disease after completing neoadjuvant chemotherapy. No unexpected safety signals were observed.
from RTT - Biotech https://ift.tt/3nFl2E6
via IFTTT
No comments:
Post a Comment